BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31312965)

  • 1. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
    Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W
    J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations.
    Tao H; Yan X; Zhu K; Zhang H
    Chem Pharm Bull (Tokyo); 2019; 67(4):382-388. PubMed ID: 30930442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
    Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening.
    Ye Y; Zhang B; Mao R; Zhang C; Wang Y; Xing J; Liu YC; Luo X; Ding H; Yang Y; Zhou B; Jiang H; Chen K; Luo C; Zheng M
    Org Biomol Chem; 2017 May; 15(17):3648-3661. PubMed ID: 28397890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
    Mao R; Shao J; Zhu K; Zhang Y; Ding H; Zhang C; Shi Z; Jiang H; Sun D; Duan W; Luo C
    J Med Chem; 2017 Jul; 60(14):6289-6304. PubMed ID: 28650658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
    Zhu K; Jiang C; Tao H; Liu J; Zhang H; Luo C
    Bioorg Med Chem Lett; 2018 May; 28(9):1476-1483. PubMed ID: 29628326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
    Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY
    Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
    Chan-Penebre E; Kuplast KG; Majer CR; Boriack-Sjodin PA; Wigle TJ; Johnston LD; Rioux N; Munchhof MJ; Jin L; Jacques SL; West KA; Lingaraj T; Stickland K; Ribich SA; Raimondi A; Scott MP; Waters NJ; Pollock RM; Smith JJ; Barbash O; Pappalardi M; Ho TF; Nurse K; Oza KP; Gallagher KT; Kruger R; Moyer MP; Copeland RA; Chesworth R; Duncan KW
    Nat Chem Biol; 2015 Jun; 11(6):432-7. PubMed ID: 25915199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations.
    Zhu K; Tao H; Song JL; Jin L; Zhang Y; Liu J; Chen Z; Jiang CS; Luo C; Zhang H
    Bioorg Chem; 2018 Dec; 81():289-298. PubMed ID: 30172110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.
    Shao J; Zhu K; Du D; Zhang Y; Tao H; Chen Z; Jiang H; Chen K; Luo C; Duan W
    Eur J Med Chem; 2019 Feb; 164():317-333. PubMed ID: 30605830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Activity of Triazole-Adenosine Analogs as Protein Arginine Methyltransferase 5 Inhibitors.
    Brown T; Cao M; Zheng YG
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety.
    Bai X; Zhai Z; Zhao X; Li R; Liang L; Jin Y; Yin Y
    Future Med Chem; 2022 Jul; 14(14):1071-1086. PubMed ID: 35748226
    [No Abstract]   [Full Text] [Related]  

  • 13. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
    Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
    Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors.
    Sun Y; Wang Z; Yang H; Zhu X; Wu H; Ma L; Xu F; Hong W; Wang H
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31390828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
    Ye F; Zhang W; Ye X; Jin J; Lv Z; Luo C
    J Chem Inf Model; 2018 May; 58(5):1066-1073. PubMed ID: 29672052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of PRMT5 inhibitors with novel scaffold structures through virtual screening and biological evaluations.
    Zhang Q; Zhang L; Jin J; Fan Y; Wang X; Hu H; Ye X; Wang L; Cao C; Ye F
    J Mol Model; 2022 Jun; 28(7):184. PubMed ID: 35680707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-yl)anilines Core Identified by Virtual Screening and Biological Evaluation.
    Zhang Y; Zhu K; Zhang J; Zhang JH; Song Z; Zhang X; Liu SK; Jiang CS
    Curr Pharm Des; 2023; 29(6):474-479. PubMed ID: 36790004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRMT1 loss sensitizes cells to PRMT5 inhibition.
    Gao G; Zhang L; Villarreal OD; He W; Su D; Bedford E; Moh P; Shen J; Shi X; Bedford MT; Xu H
    Nucleic Acids Res; 2019 Jun; 47(10):5038-5048. PubMed ID: 30916320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
    Fu S; Zheng Q; Zhang D; Lin C; Ouyang L; Zhang J; Chen L
    Eur J Med Chem; 2022 Dec; 244():114842. PubMed ID: 36274274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
    Brehmer D; Beke L; Wu T; Millar HJ; Moy C; Sun W; Mannens G; Pande V; Boeckx A; van Heerde E; Nys T; Gustin EM; Verbist B; Zhou L; Fan Y; Bhargava V; Safabakhsh P; Vinken P; Verhulst T; Gilbert A; Rai S; Graubert TA; Pastore F; Fiore D; Gu J; Johnson A; Philippar U; Morschhäuser B; Walker D; De Lange D; Keersmaekers V; Viellevoye M; Diels G; Schepens W; Thuring JW; Meerpoel L; Packman K; Lorenzi MV; Laquerre S
    Mol Cancer Ther; 2021 Dec; 20(12):2317-2328. PubMed ID: 34583982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.